Trial Profile

A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acoltremon (Primary)
Indications Dry eyes
Focus Registrational; Therapeutic Use
Acronyms COMET-3
Sponsors Aerie Pharmaceuticals; Alcon

Most Recent Events

17 Apr 2025 According to an Alcon media release, the data from this study will be presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 25-28, in Los Angeles.
09 Jan 2024 According to Alcon media release, Primary endpoint (Unanesthetized Schirmer test) has been met.
09 Jan 2024 Topline Results presented in the Alcon Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com